Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia. [PDF]
Hou JZ +16 more
europepmc +1 more source
Zanubrutinib, obinutuzumab, and venetoclax in CLL: long-term follow up, MRD kinetics, retreatment, T-cell profiling, and PKs. [PDF]
Soumerai JD +60 more
europepmc +1 more source
Crystalline κ-light-chain proximal tubulopathy in Waldenström macroglobulinemia with an IgA nephropathy pattern: a case report and systematic review. [PDF]
Zhang J +8 more
europepmc +1 more source
BTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives. [PDF]
Robak T, Wolska-Washer A, Robak P.
europepmc +1 more source
Pulmonary Involvement in Chronic Lymphocytic Leukemia: A Structured Diagnostic Approach to Diffuse Infiltrates-A Case Report. [PDF]
Aguado B +4 more
europepmc +1 more source
Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up. [PDF]
Shadman M +9 more
europepmc +1 more source
Three generations, one target: BTK inhibitors in lymphoma. [PDF]
Schmitt A, Hailfinger S.
europepmc +1 more source
Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells. [PDF]
Pizzarella D +18 more
europepmc +1 more source
Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B-cell malignancies: A nationwide population-based study. [PDF]
Zelmat Y +5 more
europepmc +1 more source

